Page 127 - NobleCon21

NRx Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS NRXP
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue NA NA NA 0.24 0.24
Gross Profit NA NA NA 0.15 0.15
Gross Margin NM NM NM 60% 60%
EBIT (3.63) (3.75) (3.73) (4.12) (15.23)
EBIT Margin NM NM NM -1702% -6293%
Net Income to Common Shareholders (9.08) (5.51) (17.58) (5.89) (38.06)
Net Margin NM NM NM -2434% -15728%

Balance Sheet Key Items
Total Assets 3.65 7.59 4.84 15.00 15.00
Cash & Short Term Investments 1.44 5.55 2.91 7.18 7.18
% of Assets 40% 73% 60% 48% 48%
Current Assets -Total 3.30 7.26 4.59 11.95 11.95
% of Assets 90% 96% 95% 80% 80%
Total Liabilities 26.87 32.75 40.45 40.75 40.75
% of Assets 736% 432% 836% 272% 272%
Current Liabilities - Total 21.86 32.75 40.45 40.59 40.59
% of Assets 599% 432% 836% 271% 271%
Long Term Debt 5.01 NA NA NA NA
% of Assets 137% NM NM NM NM
Total Equity (23.22) (25.16) (35.62) (25.76) (25.76)
% of Assets -636% -332% -736% -172% -172%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (2.10) (3.48) (4.03) (2.89) (12.50)
Net Cash Flow - Investing NA NA NA (2.56) (2.56)
Net Cash Flow - Financing 1.90 7.59 1.39 9.73 20.60

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference